Results 51 to 60 of about 863,493 (265)

Boosting antibody therapy with complement [PDF]

Blood, 2012
In this issue of Blood, Elvington et al present a method to enhance complement activation during antibody therapy of cancer. Using a fusion protein of a complement receptor and an IgG Fc fragment, therapeutic outcome was improved in vivo.
Peter, Boross, Jeanette H W, Leusen
openaire   +2 more sources

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches

Frontiers in Immunology
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related deaths worldwide, underscoring the urgent need for innovative therapeutic strategies.
Sherif A. El-Kafrawy, Sherif A. El-Kafrawy, Mostafa S. Elkafrawy, Esam I. Azhar, Esam I. Azhar, Anwaar Saeed, Ashraf A. Tabll, Ashraf A. Tabll   +7 more
doaj   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

Epidemiological overview, advances in diagnosis, prevention, treatment and management of epithelial ovarian cancer in Mexico

Salud Pública de México, 2016
The epithelial ovarian cancer (EOC) has been underdiagnosed because it does not have a specific clinical presentation, and the signs and symptoms are similar to the irritable bowel syn- drome and pelvic inflammatory disease.
Dolores Gallardo-Rincón, Raquel Espinosa-Romero, Wendy Rosemary Muñoz, Roberto Mendoza-Martínez, Susana del Villar-Álvarez, Luis Oñate-Ocaña, David Isla-Ortiz, Juan Pablo Márquez-Manríquez, Ángel Apodaca-Cruz, Abelardo Meneses-García   +9 more
doaj  

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source

DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma

eLife
Diffuse large B-cell lymphoma (DLBCL) is a common aggressive form of non-Hodgkin lymphoma. Tetraspanin CD37 is highly expressed on mature B cells and being studied as a therapeutic target for NHL, including DLBCL.
Simar Pal Singh, Kumar Mangalam, Michelle D van den Beukel, Sjoerd van Deventer, Marije B Overdijk, M Guy Roukens, Kim CM Santegoets, Esther CW Breij, Martin ter Beest, Willem PJ Cox, Annemiek B van Spriel   +10 more
doaj   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Radiolabeled antibody therapy

Seminars in Oncology Nursing, 1987
Summary To summarize, radiolabeled antibodies are used as an experimental therapy to treat certain tumors that have tumor-associated antigens. Preliminary phase I–II studies have shown that radiolabeled antibodies did bring about a remission in some individuals while also avoiding many side effects.
openaire   +2 more sources

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source